Copy to clipboard 
Tenon Medical acquired sacroiliac (SI) joint-specific assets from SiVantage, a privately held startup company. Integration activities will commence immediately and will complete in 4Q25.
This strategic asset acquisition includes SiVantage’s SImmetry and SImmetry+ technologies, expanding Tenon’s SI portfolio across multiple approaches to the variable sacro pelvic anatomy. These differentiated technologies enable physicians to customize treatment plans for their patients using novel authentic fusion products backed by clinical data.
Transaction Highlights
- Transaction moves critical technologies, intellectual property, and commercial leadership of SiVantage to Tenon Medical.
- Core technology products are expected to contribute to revenue immediately.
- Enhanced product pipeline is significantly strengthened, accelerating innovation and market readiness.
- Supported by extensive clinical data, the integrated platform demonstrates a proven record of safety and performance.
Tenon is now a multi-product, multi-approach sacro-pelvic organization.
SiVantage Co-Founders Wyatt Geist and Nate Grawey are joining Tenon’s management team as Chief Innovations Officer and Chief Commercial Officer, respectively.
The transaction structure includes a modest upfront cash component and an equity issuance representing a percentage of shares outstanding, with the majority of total consideration contingent upon achieving future performance milestones.
“The sacro pelvic fusion space is evolving very quickly. As our physician customers define their needs, Tenon Medical will deliver innovative solutions backed by clinical data to emerge as a leader in this high growth space.” said Steve Foster, Chief Executive Officer of Tenon Medical. “With the addition of extraordinary people and a pipeline of innovative solutions, Tenon is now a multi-product and multi-approach sacro-pelvic organization that is poised for growth. We are laser focused on innovative solutions that deliver authentic fusion principals in a format with a strong safety profile backed by biomechanical and clinical data.”
Wyatt Geist, CEO and Co-Founder of SiVantage and a recognized entrepreneur in the space with over one hundred patents to his name stated, “I am extremely excited to work with this data driven team to deliver exciting innovative technologies. It became clear in our early discussions with Tenon that we shared visions and values focused on collaborating with ethical partners to redefine sacroiliac fusion and deliver safe, effective solutions that enhance patient outcomes and provide unparalleled surgical reproducibility.”
Nate Grawey, President and Co-Founder of SiVantage added, “Tenon’s platform is THE perfect fit for SImmetry and the soon to be launched SImmetry+. This combined company will offer a differentiated portfolio that physicians want, administrators approve and payors value.”
Source: Tenon Medical, Inc.
Tenon Medical acquired sacroiliac (SI) joint-specific assets from SiVantage, a privately held startup company. Integration activities will commence immediately and will complete in 4Q25.
This strategic asset acquisition includes SiVantage's SImmetry and SImmetry+ technologies, expanding Tenon's SI portfolio across multiple approaches to the...
Tenon Medical acquired sacroiliac (SI) joint-specific assets from SiVantage, a privately held startup company. Integration activities will commence immediately and will complete in 4Q25.
This strategic asset acquisition includes SiVantage’s SImmetry and SImmetry+ technologies, expanding Tenon’s SI portfolio across multiple approaches to the variable sacro pelvic anatomy. These differentiated technologies enable physicians to customize treatment plans for their patients using novel authentic fusion products backed by clinical data.
Transaction Highlights
- Transaction moves critical technologies, intellectual property, and commercial leadership of SiVantage to Tenon Medical.
- Core technology products are expected to contribute to revenue immediately.
- Enhanced product pipeline is significantly strengthened, accelerating innovation and market readiness.
- Supported by extensive clinical data, the integrated platform demonstrates a proven record of safety and performance.
Tenon is now a multi-product, multi-approach sacro-pelvic organization.
SiVantage Co-Founders Wyatt Geist and Nate Grawey are joining Tenon’s management team as Chief Innovations Officer and Chief Commercial Officer, respectively.
The transaction structure includes a modest upfront cash component and an equity issuance representing a percentage of shares outstanding, with the majority of total consideration contingent upon achieving future performance milestones.
“The sacro pelvic fusion space is evolving very quickly. As our physician customers define their needs, Tenon Medical will deliver innovative solutions backed by clinical data to emerge as a leader in this high growth space.” said Steve Foster, Chief Executive Officer of Tenon Medical. “With the addition of extraordinary people and a pipeline of innovative solutions, Tenon is now a multi-product and multi-approach sacro-pelvic organization that is poised for growth. We are laser focused on innovative solutions that deliver authentic fusion principals in a format with a strong safety profile backed by biomechanical and clinical data.”
Wyatt Geist, CEO and Co-Founder of SiVantage and a recognized entrepreneur in the space with over one hundred patents to his name stated, “I am extremely excited to work with this data driven team to deliver exciting innovative technologies. It became clear in our early discussions with Tenon that we shared visions and values focused on collaborating with ethical partners to redefine sacroiliac fusion and deliver safe, effective solutions that enhance patient outcomes and provide unparalleled surgical reproducibility.”
Nate Grawey, President and Co-Founder of SiVantage added, “Tenon’s platform is THE perfect fit for SImmetry and the soon to be launched SImmetry+. This combined company will offer a differentiated portfolio that physicians want, administrators approve and payors value.”
Source: Tenon Medical, Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
